Literature DB >> 31448866

The prevalence and predictors of resistant hypertension in high-risk overweight and obese patients: A cross-sectional study based on the 2017 ACC/AHA guidelines.

Faris Haddadin1, Karan Sud1, Alba Munoz Estrella1, Sananda Moctezuma1, Lingling Wu1, Joshua Berookhim1, Claire Huang Lucas1, Dipal Patel1, Edgar Argulian2.   

Abstract

Obesity is significantly associated with uncontrolled blood pressure and resistant hypertension (RH). There are limited studies on the prevalence and determinants of RH in patients with higher body mass index (BMI) values. Since the hypertension guidelines changed in 2017, the prevalence of RH has become unknown and now is subject to be estimated by further studies. We conducted a cross-sectional study in an urban Federally Qualified Health Center in New York City aiming to estimate the prevalence of RH in high-risk overweight and obese patients based on the new hypertension definition, BP threshold ≥130/80 mm Hg, and also to describe the associated comorbid conditions in these patients. We identified 761 eligible high-risk overweight and obese subjects with hypertension between October 2017 and October 2018. Apparent treatment-RH was found in 13.6% among the entire study population. This represented 15.4% of those treated with BP-lowering agents. True RH confirmed with out-of-office elevated BP was found in 6.7% of the study population and 7.4% among patients treated with BP-lowering agents. Prevalence was higher with higher BMI values. Those with true RH were more likely to be black, to have diabetes mellitus requiring insulin, chronic kidney disease stage 3 or above and diastolic heart failure. In conclusion, obesity is significantly associated with RH and other significant metabolic comorbid conditions. ©2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  obese; overweight; resistant hypertension

Mesh:

Substances:

Year:  2019        PMID: 31448866      PMCID: PMC8030605          DOI: 10.1111/jch.13666

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  39 in total

Review 1.  Obesity.

Authors:  David W Haslam; W Philip T James
Journal:  Lancet       Date:  2005-10-01       Impact factor: 79.321

Review 2.  Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis.

Authors:  Hannah Durand; Peter Hayes; Eimear C Morrissey; John Newell; Monica Casey; Andrew W Murphy; Gerard J Molloy
Journal:  J Hypertens       Date:  2017-12       Impact factor: 4.844

3.  Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.

Authors:  Alejandro de la Sierra; Julián Segura; José R Banegas; Manuel Gorostidi; Juan J de la Cruz; Pedro Armario; Anna Oliveras; Luis M Ruilope
Journal:  Hypertension       Date:  2011-03-28       Impact factor: 10.190

4.  Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004.

Authors:  Jun Ma; Ky-Van Lee; Randall S Stafford
Journal:  Hypertension       Date:  2006-09-18       Impact factor: 10.190

5.  Self-blood pressure monitoring in an urban, ethnically diverse population: a randomized clinical trial utilizing the electronic health record.

Authors:  Stella S Yi; Bahman P Tabaei; Sonia Y Angell; Anne Rapin; Michael D Buck; William G Pagano; Frank J Maselli; Alvaro Simmons; Shadi Chamany
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-03-03

6.  Prevalence of resistant hypertension in the United States, 2003-2008.

Authors:  Stephen D Persell
Journal:  Hypertension       Date:  2011-04-18       Impact factor: 10.190

7.  Prevalence, clinical characteristics and echocardiography parameters of non-resistant, resistant and refractory hypertension in Chinese.

Authors:  Gaozhen Cao; Cong Chen; Qingshan Lin; Yan Chen; Zhe Zhen; Yuan Zou; Juhua Liu; Min Wu; Run Wang; Mingya Liu; Chunting Zhao; Shukun Lu; Ming-Yen Ng; Hung-Fat Tse; Kai-Hang Yiu
Journal:  Postgrad Med       Date:  2016-12-28       Impact factor: 3.840

8.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

9.  Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting.

Authors:  Carrie McAdam-Marx; Xiangyang Ye; Jennifer C Sung; Diana I Brixner; Kristijan H Kahler
Journal:  Clin Ther       Date:  2009-05       Impact factor: 3.393

10.  Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study.

Authors:  Costas Tsioufis; Alexandros Kasiakogias; Athanasios Kordalis; Kyriakos Dimitriadis; Costas Thomopoulos; Dimitrios Tsiachris; Panagiotis Vasileiou; Michalis Doumas; Thomas Makris; Vasilios Papademetriou; Ioannis Kallikazaros; George Bakris; Christodoulos Stefanadis
Journal:  J Hypertens       Date:  2014-02       Impact factor: 4.844

View more
  2 in total

1.  Obesity and resistant hypertension: Never ending story.

Authors:  Marijana Tadic; Cesare Cuspidi
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-26       Impact factor: 3.738

2.  The prevalence and predictors of resistant hypertension in high-risk overweight and obese patients: A cross-sectional study based on the 2017 ACC/AHA guidelines.

Authors:  Faris Haddadin; Karan Sud; Alba Munoz Estrella; Sananda Moctezuma; Lingling Wu; Joshua Berookhim; Claire Huang Lucas; Dipal Patel; Edgar Argulian
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-26       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.